Piramal Pharma Solutions (PPS) is investing $32 million to expand its facility in Riverview, MI with additional capacity and new capabilities for the development and manufacture of Active Pharmaceutical Ingredients (APIs).

The 25,000 sq.-ft. expansion includes 8,500 sq.-ft. of production space, and capacity will increase in large-scale manufacturing with the addition of new reactors capable of handling up to 4000L. PPS is also adding two new kilo labs for process development and GMP manufacture for clinical trials at scales up to 100L.

The expansion is scheduled to be operational beginning Summer 2022. The company plans to add approximately twenty new hires to the site, bringing the total headcount to more than 180. This would be the seventh major acquisition or expansion by PPS in North America in the past six years.

Equipment
New equipment includes a 1m2 filter dryer with glovebox technology, 3KL/4KL mild steel glass lined reactor and 3KL Hastelloy reactor, all designed to handle potent compounds with OELs >1mcg/m3. Facility design procedures assure all appropriate safety measures, including controlled room pressurizations with air locks for safe movement of both people and materials, glovebox technology/contained systems for charging and discharging of potent compounds, and a scrubber to address any reaction off-gassing.

Peter DeYoung, CEO, Piramal Pharma Solutions said, “Piramal Pharma Solutions’ Riverview facility has a well-earned reputation as the preeminent leader in high potency APIs (HPAPIs), and this expansion is designed to ensure that we retain that position. It enables us to support our customers’ immediate and long-term API needs, strengthens our presence in North America, and enhances our ability to serve patients around the world by delivering the best active ingredients in a timely manner.”